Pharmacodynamics (PD) refers to the biological response of human body to drugs, which is described by biochemical or molecular interactions and physiologic effects. In short, PD is to discover how the drug affects the organism. The main pharmacodynamic effects of drugs are reflected by appropriate in vitro and in vivo models according to the classification and pharmacological characteristics of drugs. Pharmacodynamics particular emphasizes the dose–response relationship which describes the relationship between drug concentration and effect. Pharmacodynamic studies can be performed either at cellular level or in animal models. The development of pharmacodynamic assays included in the evaluation of the drug efficacy should be initiated at very early stage to support drug discovery and development efforts.
Figure 1. Depiction of pharmacodynamic parameters over a concentration time profile. (Kuti, J. L., 2016)
Creative Biolabs provides professional pharmacodynamic services for efficacy evaluation of drug research and development thus to deal with data reproducibility crisis which is a big obstacle for drug research and development and may lead to failure and high risk of investment. With our professional PD studies, we can drive forward and speed up your drug discovery and development process.
Creative Biolabs offers comprehensive pharmacodynamic services, including but not limited to the following:
Anticancer Drug Pharmacodynamics
As malignant tumors are life-threatening and the death rate from these diseases remains high, it is desirable to provide new, effective anticancer drugs to patients more expeditiously. However, the attrition rate of new anticancer drugs in clinical trials is disappointingly high. Thus, the predictive value of preclinical models assumes critical importance in cancer drug development. We are dedicated to offering pharmacodynamic services for anticancer drug development. We provide cell-based studies and different cancer models to evaluate the efficacy of anticancer drugs both in vitro and in vivo.
Cardiovascular Drug Pharmacodynamics
The biological mechanisms leading to cardiovascular disease are complex and span several key biological systems. Although advances in the prevention and treatment of cardiovascular disease have contributed to a decline in mortality rates, cardiovascular disease remains the leading cause of death all over the world. Recently, a revival of cardiovascular drug development has introduced new treatment options to the market. To screen safety and effective drugs for the treatment of cardiovascular diseases, we offer a package of pharmacodynamic services based on comprehensive cell services and various animal models of cardiovascular diseases.
Metabolic and Endocrine Disease Drug Pharmacodynamics
The incidence of metabolic and endocrine diseases is increasing all over the world, particularly in advanced countries. Obesity and diabetes, which belong to metabolic and endocrine diseases, are among the fastest growing epidemics in the world. There’s no single effective drug treatment for this group of disease yet, and more attention focuses on the new drug discovery and development. Understanding PD is helpful to provide considerations for the choice of drugs and concentration used. As a top-ranking leader in preclinical trials, we can provide our clients with extensive pharmacodynamic services and analysis for metabolic and endocrine diseases.
Respiratory Disease Drug Pharmacodynamics
Respiratory diseases are amongst the leading causes of death globally and represent an enormous and increasing healthcare burden. However, respiratory diseases remain a considerable unmet medical need. As a service provider with high reputations, we are dedicated to exploring the basic principles of pharmacodynamics in respiratory diseases and are capable of offering accurate pharmacology assays based on various cell services and different animal models of respiratory disease.
Antimicrobial Drug Pharmacodynamics
Infectious diseases are a leading cause of death worldwide. The treatment of many infections has been challenged by the increasing resistance of pathogens to antimicrobial drugs. Therefore, there is an urgent need to develop new antimicrobial drugs to solve the problem of drug resistance. Our scientific team can provide professional in vitro and in vivo pharmacodynamic services for antimicrobial drugs to help you determine microbiological characters and efficacy of drug candidates. We have established various infectious disease models to help our clients develop safe and effective drug.
Neurological Drug Pharmacodynamics
Neurological diseases refer to disorders or dysfunctions within the nervous system and are found to be the largest cause of disability worldwide. Prevention and effective treatment of neurological disorders has been a major medical challenge. With years of experience in the field of neurological drug discovery, we are capable of offering a full package of pharmacodynamic services, including cell-based studies and in vivo studies in neurological disease models.
Anti-inflammatory Drug Pharmacodynamics
Inflammation is part of the complex biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or stimulants. Inappropriately triggering or incomplete control of inflammation is a major cause of disease. Creative Biolabs is committed to anti-inflammatory drug discovery and skilled at assessing multiple pharmacological parameters to lower risks through drug development. We have professional scientists particularly adept at PD assessments for anti-inflammatory drugs.
Creative Biolabs has a dedicated assay development team that will work closely with you to design customized assays. Our service will meet your specific needs fast at extremely competitive prices. If you need more information, please feel free to contact us at anytime. We look forward to working with you to help your drug research and development project succeed.
Kuti, J. L., 2016. Optimizing antimicrobial pharmacodynamics: a guide for your stewardship program. Revista Médica Clínica Las Condes, 27(5), pp. 615-624.